Assessing correlation between antimicrobial resistance genes and susceptibility phenotypes for enterobacter cloacae complex isolates from the VET-lirn AMR monitoring program and clinical samples
Ended Cooperative Agreement Awarded Last action
- Award ID
- U18FD008360
- Recipient
-
Kansas State University UEI CFMMM5JM7HJ9
- Awarding agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Obligated
- $100,000
Award facts
- Assistance listing
- 93.103 Food and Drug Administration Research
- Completion date
- Originally
- Funding agency
- Food and Drug Administration Department of Health and Human Services
- Place of performance
- Kansas, USA
Award details come from USAspending.gov.
Description
- Abstract
- Enterobacter cloacae complex (ECC) are a natural component of mammalian gastrointestinal microbiota (davin-regli and pagès, 2015; ramirez and giron, 2020), but also found in a wide range of foods and can potentially serve as foodborne pathogens (healy ET AL., 2010; shaker ET AL., 2007; capita ET AL., 2020; gwida ET AL., 2014; kilonzo-nthenge ET AL., 2013). A recent study has identified multi-drug resistant ECC in raw tomatoes, lettuce, carrots and other fresh vegetables that were intended for direct human consumption in spain (pintor-cora ET AL., 2023). ECC and e. Aerogenes are recognized as the most predominant nosocomial clinical pathogens within the enterobacter genus, often linked to infection outbreaks (davin-regli and pagès, 2015; mezzatesta ET AL., 2012). Over the past three decades, they emerged as highly significant opportunistic, and multi-drug resistant pathogens in hospital settings (gaston, 1988). These infections, ranging from urinary tract infections, pneumonia, bacteremia, and sepsis, pose significant risks particularly for immunocompromised individuals (annavajhala ET AL., 2019; girlich ET AL., 2021; intra ET AL., 2023). Antimicrobial resistance (AMR) in enterobacteriaceae represents a global public health concern (john JR ET AL., 1982; ramirez and giron, 2020). Klebsiella species and enterobacter species, including ECC isolates, are recognized as the most prevalent carbapenem-resistant enterobacteriaceae (CRE) in the united states (annavajhala ET AL., 2019; lutgring, 2019; mezzatesta ET AL., 2012). In recent years, many antibiotics commonly used to treat enterobacter infections, including ECC- associated diseases, have been alarmingly less effective(sanders JR and sanders, 1997). This trend is attributed to the intrinsic β-lactam resistance observed in ECC species, primarily due to expression of low levels of ampc genes encoding for an inducible ampc-type cephalosporinase (annavajhala ET AL., 2019; seeberg ET AL., 1983). This unique chromosomal β-lactam mechanism enables ECC species to resist the bactericidal effect of penicillins and first- and second-generation cephalosporins. In cases of prolonged exposure to β-lactam drugs, ECC species may even exhibit resistance to third generation cephalosporins (seeberg ET AL., 1983). The VET-lirn AMR monitoring program has collected and sequenced approximately 200 ECC strains, and determined their corresponding AMR phenotypes. Ksvdl routinely receives ECC-positive diagnostic samples. The objectives of this project are to isolate ~20 ECC isolates from ksvdl submitted specimens, obtain genome sequences and determine AMR phenotypes, then perform a comparative analysis of AMR phenotypes of these ECC genome sequences alongside the 200 ECC strains from the VET-lirn AMR monitoring program.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $50,000 | |
| Original award | $50,000 |
Quick answers
Who received award U18FD008360?
U18FD008360 was awarded to Kansas State University by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 1, 2024.
How much is award U18FD008360 worth?
$100,000 has been obligated on U18FD008360.
Which agency awarded U18FD008360?
FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded U18FD008360, with funding from Food and Drug Administration (Department of Health and Human Services).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award